RU2700929C2 - Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент - Google Patents
Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент Download PDFInfo
- Publication number
- RU2700929C2 RU2700929C2 RU2016147527A RU2016147527A RU2700929C2 RU 2700929 C2 RU2700929 C2 RU 2700929C2 RU 2016147527 A RU2016147527 A RU 2016147527A RU 2016147527 A RU2016147527 A RU 2016147527A RU 2700929 C2 RU2700929 C2 RU 2700929C2
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- seq
- sequence represented
- chemotherapeutic agent
- amino acid
- Prior art date
Links
- 108010014186 ras Proteins Proteins 0.000 title claims abstract description 99
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 87
- 229940127089 cytotoxic agent Drugs 0.000 title claims abstract description 83
- 230000035772 mutation Effects 0.000 title description 176
- 229940023041 peptide vaccine Drugs 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 492
- 102000016914 ras Proteins Human genes 0.000 claims abstract description 139
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 106
- 230000001399 anti-metabolic effect Effects 0.000 claims abstract description 80
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 69
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 230000028993 immune response Effects 0.000 claims abstract description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 34
- 102200006532 rs112445441 Human genes 0.000 claims abstract description 28
- 238000006467 substitution reaction Methods 0.000 claims abstract description 25
- 102200006540 rs121913530 Human genes 0.000 claims abstract description 22
- 102200006531 rs121913529 Human genes 0.000 claims abstract description 21
- 102200006537 rs121913529 Human genes 0.000 claims abstract description 21
- 102200006539 rs121913529 Human genes 0.000 claims abstract description 21
- 102200006538 rs121913530 Human genes 0.000 claims abstract description 21
- 102200006541 rs121913530 Human genes 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 239000012634 fragment Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 102220014333 rs112445441 Human genes 0.000 claims abstract description 14
- 102200006533 rs121913535 Human genes 0.000 claims abstract description 14
- 102220197834 rs121913535 Human genes 0.000 claims abstract description 10
- 102220014328 rs121913535 Human genes 0.000 claims abstract 5
- 102220197833 rs112445441 Human genes 0.000 claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 112
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 44
- 229960005277 gemcitabine Drugs 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 19
- 201000002528 pancreatic cancer Diseases 0.000 claims description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 230000000977 initiatory effect Effects 0.000 claims description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 150000003230 pyrimidines Chemical class 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 2
- 125000000539 amino acid group Chemical group 0.000 description 59
- 238000002360 preparation method Methods 0.000 description 34
- 102200006657 rs104894228 Human genes 0.000 description 19
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 16
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- -1 inorganic acid salts Chemical class 0.000 description 12
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 9
- 102220197780 rs121434596 Human genes 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 102200006520 rs121913240 Human genes 0.000 description 2
- 102200006525 rs121913240 Human genes 0.000 description 2
- 102200007373 rs17851045 Human genes 0.000 description 2
- 102200006648 rs28933406 Human genes 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010026288 GTP Phosphohydrolases Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000686246 Homo sapiens Ras-related protein R-Ras Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100024683 Ras-related protein R-Ras Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167265 | 2014-05-06 | ||
| EP14167265.9 | 2014-05-06 | ||
| PCT/EP2015/059861 WO2015169804A1 (en) | 2014-05-06 | 2015-05-05 | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016147527A RU2016147527A (ru) | 2018-06-08 |
| RU2016147527A3 RU2016147527A3 (enExample) | 2019-01-21 |
| RU2700929C2 true RU2700929C2 (ru) | 2019-09-24 |
Family
ID=50679896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147527A RU2700929C2 (ru) | 2014-05-06 | 2015-05-05 | Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9757439B2 (enExample) |
| EP (1) | EP3140320B1 (enExample) |
| JP (2) | JP2017514847A (enExample) |
| KR (1) | KR20170002563A (enExample) |
| CN (1) | CN106414493A (enExample) |
| AU (1) | AU2015257774B2 (enExample) |
| BR (1) | BR112016025764A2 (enExample) |
| CA (1) | CA2947963A1 (enExample) |
| CL (1) | CL2016002794A1 (enExample) |
| DK (1) | DK3140320T3 (enExample) |
| ES (1) | ES2716923T3 (enExample) |
| IL (1) | IL248671B (enExample) |
| MX (1) | MX2016014414A (enExample) |
| RU (1) | RU2700929C2 (enExample) |
| SG (2) | SG10201809701TA (enExample) |
| WO (1) | WO2015169804A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
| EP3532070A1 (en) | 2016-10-26 | 2019-09-04 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| EP3576780A1 (en) * | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| EP3576764A4 (en) * | 2017-02-03 | 2020-12-16 | The Medical College of Wisconsin, Inc. | KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE |
| WO2019246286A1 (en) | 2018-06-19 | 2019-12-26 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| CN109550044B (zh) * | 2018-10-19 | 2022-05-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| WO2020252039A1 (en) * | 2019-06-12 | 2020-12-17 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| WO2022026620A1 (en) * | 2020-07-29 | 2022-02-03 | Sqz Biotechnologies Company | Methods to stimulate immune responses to mutant ras using nucleated cells |
| EP4188425B1 (en) * | 2020-07-29 | 2025-05-14 | Stemcell Technologies Canada Inc. | Methods to stimulate immune responses to mutant ras using anucleate cells |
| AU2021389909A1 (en) * | 2020-11-24 | 2023-06-22 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| JP2024541968A (ja) * | 2021-10-28 | 2024-11-13 | ジェネンテック， インコーポレイテッド | 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法 |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| WO2025103205A1 (en) * | 2023-11-15 | 2025-05-22 | Ck Life Sciences Development Limited | Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014756A1 (en) * | 1991-02-26 | 1992-09-03 | Norsk Hydro A.S | Therapeutically useful peptides and peptides fragments |
| WO2000066153A1 (en) * | 1999-04-30 | 2000-11-09 | Norsk Hydro Asa | RAS ONCOGEN p21 PEPTIDE VACCINES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| KR101241272B1 (ko) | 2002-12-16 | 2013-03-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 면역 요법으로서의 효모계 백신 |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
-
2015
- 2015-05-05 KR KR1020167034070A patent/KR20170002563A/ko not_active Withdrawn
- 2015-05-05 RU RU2016147527A patent/RU2700929C2/ru active
- 2015-05-05 WO PCT/EP2015/059861 patent/WO2015169804A1/en not_active Ceased
- 2015-05-05 US US15/308,917 patent/US9757439B2/en not_active Expired - Fee Related
- 2015-05-05 SG SG10201809701TA patent/SG10201809701TA/en unknown
- 2015-05-05 BR BR112016025764-2A patent/BR112016025764A2/pt not_active IP Right Cessation
- 2015-05-05 ES ES15720986T patent/ES2716923T3/es active Active
- 2015-05-05 AU AU2015257774A patent/AU2015257774B2/en not_active Ceased
- 2015-05-05 MX MX2016014414A patent/MX2016014414A/es unknown
- 2015-05-05 JP JP2016565676A patent/JP2017514847A/ja active Pending
- 2015-05-05 CN CN201580023165.3A patent/CN106414493A/zh active Pending
- 2015-05-05 SG SG11201608712PA patent/SG11201608712PA/en unknown
- 2015-05-05 EP EP15720986.7A patent/EP3140320B1/en not_active Revoked
- 2015-05-05 DK DK15720986.7T patent/DK3140320T3/en active
- 2015-05-05 CA CA2947963A patent/CA2947963A1/en not_active Abandoned
-
2016
- 2016-11-01 IL IL248671A patent/IL248671B/en unknown
- 2016-11-04 CL CL2016002794A patent/CL2016002794A1/es unknown
-
2020
- 2020-02-27 JP JP2020032081A patent/JP7304629B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014756A1 (en) * | 1991-02-26 | 1992-09-03 | Norsk Hydro A.S | Therapeutically useful peptides and peptides fragments |
| WO2000066153A1 (en) * | 1999-04-30 | 2000-11-09 | Norsk Hydro Asa | RAS ONCOGEN p21 PEPTIDE VACCINES |
Non-Patent Citations (2)
| Title |
|---|
| Réjiba S. et al. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment // Cancer Sci. 2007 Jul;98(7):1128-36. Strimpakos AS. et al. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? // JOP. 2013 Jul 10;14(4):354-8. * |
| Réjiba S. et al. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment // Cancer Sci. 2007 Jul;98(7):1128-36. Strimpakos AS. et al. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? // JOP. 2013 Jul 10;14(4):354-8. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015257774B2 (en) | 2018-12-20 |
| SG11201608712PA (en) | 2016-11-29 |
| JP7304629B2 (ja) | 2023-07-07 |
| RU2016147527A (ru) | 2018-06-08 |
| ES2716923T3 (es) | 2019-06-18 |
| KR20170002563A (ko) | 2017-01-06 |
| CA2947963A1 (en) | 2015-11-12 |
| CL2016002794A1 (es) | 2017-06-09 |
| EP3140320B1 (en) | 2018-12-26 |
| DK3140320T3 (en) | 2019-04-15 |
| US20170065694A1 (en) | 2017-03-09 |
| BR112016025764A2 (pt) | 2018-01-16 |
| US9757439B2 (en) | 2017-09-12 |
| IL248671B (en) | 2021-08-31 |
| AU2015257774A1 (en) | 2016-12-22 |
| RU2016147527A3 (enExample) | 2019-01-21 |
| SG10201809701TA (en) | 2018-12-28 |
| JP2020100650A (ja) | 2020-07-02 |
| MX2016014414A (es) | 2017-02-23 |
| EP3140320A1 (en) | 2017-03-15 |
| WO2015169804A1 (en) | 2015-11-12 |
| JP2017514847A (ja) | 2017-06-08 |
| IL248671A0 (en) | 2017-01-31 |
| CN106414493A (zh) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| JP7491965B2 (ja) | ネオ抗原およびその使用方法 | |
| ES2566011T3 (es) | Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo | |
| WO2008147482A2 (en) | Methods and compositions for improving immune responses | |
| JP6294459B2 (ja) | 骨髄性白血病の処置方法 | |
| JP2016536300A (ja) | Ｆｌｔ３変異を有する急性骨髄性白血病の治療方法 | |
| Zheng et al. | A novel enemy of cancer: recent investigations into protozoan anti-tumor properties | |
| CN101171032A (zh) | 天然肽及其优化的衍生物作为疫苗的应用 | |
| US20230181633A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2018160666A1 (en) | Short-term activated dc1s and methods for their production and use | |
| HK1231899B (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
| HK1231899A1 (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
| CN113966227A (zh) | 疫苗佐剂以及制剂 | |
| US20250000971A1 (en) | Tlr4 agonist for modulating immune response | |
| KR102960889B1 (ko) | 백신 보조제 및 제형 | |
| RU2773273C2 (ru) | Неоантигены и способы их использования | |
| WO2023056337A1 (en) | Tlr8 agonist for modulating immune response | |
| TWI658832B (zh) | 用於抑制骨髓衍生抑制細胞之組成物 | |
| Zinzani | 14 Recent progress in the treatment for T-cell malignancies | |
| HK40004257A (en) | Neoantigens and methods of their use |